Cargando…
Bcl-2 family inhibition sensitizes human prostate cancer cells to docetaxel and promotes unexpected apoptosis under caspase-9 inhibition
Docetaxel (DTX) is a useful chemotherapeutic drug for the treatment of hormone-refractory prostate cancer. However, emergence of DTX resistance has been a therapeutic hurdle. In this study, we investigated the effect of combining DTX with Bcl-2 family inhibitors using human prostate cancer cell line...
Autores principales: | Tamaki, Hiroki, Harashima, Nanae, Hiraki, Miho, Arichi, Naoko, Nishimura, Nobuhiro, Shiina, Hiroaki, Naora, Kohji, Harada, Mamoru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4294332/ https://www.ncbi.nlm.nih.gov/pubmed/25333266 |
Ejemplares similares
-
Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL
por: Hari, Yoko, et al.
Publicado: (2015) -
Versican is a potential therapeutic target in docetaxel-resistant prostate cancer
por: Arichi, Naoko, et al.
Publicado: (2015) -
Docetaxel induces Bcl-2- and pro-apoptotic caspase-independent death of human prostate cancer DU145 cells
por: OGURA, TAKEHARU, et al.
Publicado: (2016) -
The Roles of ROS and Caspases in TRAIL-Induced Apoptosis and Necroptosis in Human Pancreatic Cancer Cells
por: Zhang, Min, et al.
Publicado: (2015) -
HIF-2α dictates the susceptibility of pancreatic cancer cells to TRAIL by regulating survivin expression
por: Harashima, Nanae, et al.
Publicado: (2017)